LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives
about
Rab GTPases: The Key Players in the Molecular Pathway of Parkinson's Disease.The LRRK2 signalling system.Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.Age-Dependent Dopaminergic Neurodegeneration and Impairment of the Autophagy-Lysosomal Pathway in LRRK-Deficient Mice.LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.LRRK2 Contributes to Secondary Brain Injury Through a p38/Drosha Signaling Pathway After Traumatic Brain Injury in Rats.
P2860
LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives
description
2016 nî lūn-bûn
@nan
2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
LRRK2 inhibitors and their pot ...... disease: current perspectives
@ast
LRRK2 inhibitors and their pot ...... disease: current perspectives
@en
LRRK2 inhibitors and their pot ...... disease: current perspectives
@nl
type
label
LRRK2 inhibitors and their pot ...... disease: current perspectives
@ast
LRRK2 inhibitors and their pot ...... disease: current perspectives
@en
LRRK2 inhibitors and their pot ...... disease: current perspectives
@nl
prefLabel
LRRK2 inhibitors and their pot ...... disease: current perspectives
@ast
LRRK2 inhibitors and their pot ...... disease: current perspectives
@en
LRRK2 inhibitors and their pot ...... disease: current perspectives
@nl
P2860
P3181
P356
P1476
LRRK2 inhibitors and their pot ...... disease: current perspectives
@en
P2093
Farzaneh Atashrazm
Nicolas Dzamko
P2860
P304
P3181
P356
10.2147/CPAA.S102191
P407
P577
2016-10-20T00:00:00Z